A randomized, open labeled, active-controlled trial of 24-week versus 48-week courses of peg-interferon alpha plus ribavirin for genotype-1 infected chronic hepatitis C patients

Trial Profile

A randomized, open labeled, active-controlled trial of 24-week versus 48-week courses of peg-interferon alpha plus ribavirin for genotype-1 infected chronic hepatitis C patients

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Jun 2008

At a glance

  • Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Jun 2008 Results have been published.
    • 24 Mar 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top